84 related articles for article (PubMed ID: 27866092)
21. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
[TBL] [Abstract][Full Text] [Related]
22. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
23. A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation.
Zhou X; Li B; Zhang Y; Gu Y; Chen B; Shi T; Ao L; Li P; Li S; Liu C; Guo Z
Breast Cancer Res Treat; 2013 Dec; 142(3):505-14. PubMed ID: 24253811
[TBL] [Abstract][Full Text] [Related]
24. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer.
Wo JY; Chen K; Neville BA; Lin NU; Punglia RS
J Clin Oncol; 2011 Jul; 29(19):2619-27. PubMed ID: 21606424
[TBL] [Abstract][Full Text] [Related]
25. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
Leone JP; Leone BA; Tayob N; Hassett MJ; Leone J; Freedman RA; Tolaney SM; Winer EP; Vallejo CT; Lin NU
Breast Cancer Res Treat; 2021 Jun; 187(3):843-852. PubMed ID: 33590387
[TBL] [Abstract][Full Text] [Related]
26. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
[TBL] [Abstract][Full Text] [Related]
27. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
29. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
30. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.
Leone JP; Graham N; Tolaney SM; Leone BA; Freedman RA; Hassett MJ; Leone J; Vallejo CT; Winer EP; Lin NU; Tayob N
Eur J Cancer; 2022 Sep; 173():20-29. PubMed ID: 35841843
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis.
Yuan C; Xie Z; Bian J; Huo J; Daily K
Breast Cancer Res Treat; 2020 Apr; 180(3):819-827. PubMed ID: 32172303
[TBL] [Abstract][Full Text] [Related]
33. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
[TBL] [Abstract][Full Text] [Related]
34. The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343.
Palta M; Palta P; Bhavsar NA; Horton JK; Blitzblau RC
Cancer; 2015 Jan; 121(2):188-93. PubMed ID: 25488523
[TBL] [Abstract][Full Text] [Related]
35. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
[TBL] [Abstract][Full Text] [Related]
37. Predictors of axillary lymph node involvement in women with T3 breast cancers: analysis of 1988-2003 SEER data.
Fields RC; Jeffe DB; Deshpande AD; Feunou F; Krishna N; Margenthaler JA
J Surg Res; 2010 Jun; 161(2):183-9. PubMed ID: 19959188
[TBL] [Abstract][Full Text] [Related]
38. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
39. [Adjuvant chemotherapy of early stage breast cancer].
Boér K
Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
[TBL] [Abstract][Full Text] [Related]
40. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
